Pricing Log in Create free account

Cellectis S.A. (CLLS) vs Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Cellectis S.A. and Corbus Pharmaceuticals Holdings, Inc. are both Biotechnology companies. Cellectis S.A. and Corbus Pharmaceuticals Holdings, Inc. are of similar size ($83.8M and $79.9M). Cellectis S.A. grew revenue faster over the last twelve months: 0.61% against −73.7%. Corbus Pharmaceuticals Holdings, Inc. has the higher net margin (0.00% vs −102.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Corbus Pharmaceuticals Holdings, Inc. leads on 9 and Cellectis S.A. on 8.

Valuation

Metric CLLS CRBP Biotechnology median
P/E n/m n/m 8.50
P/S 1.64 56.97 9.71
P/B 2.55 0.86 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.07 0.64
EV/Sales 0.18 (5.25) 9.21
Earnings yield (62.89%) (136.95%) (33.15%)
Free cash flow yield (44.14%) (98.82%) (25.50%)

Profitability

Metric CLLS CRBP Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (90.88%) 0.00% 0.00%
Net margin (102.34%) 0.00% 0.00%
Free cash flow margin (68.63%) 0.00% 0.00%
Return on equity (94.54%) (95.58%) (56.36%)
Return on assets (21.02%) (80.85%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS CRBP Biotechnology median
Revenue growth (TTM) 0.61% (73.69%) 6.02%
EPS growth (last fiscal year) (63.41%) (60.33%) 30.26%
Revenue growth, 5-year CAGR (0.70%) (14.34%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS CRBP Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 5.71 4.72
Net debt to EBITDA 9.54 1.90 0.96

Dividend

Metric CLLS CRBP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLLS CRBP Biotechnology median
Market cap 79.92m 83.75m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack